In stable MS, switching from CD20 inhibitors to fumarates may be OK

Multiple Sclerosis News Today

Factuality

Ownership

In stable MS, switching from CD20 inhibitors to fumarates may be OK

Switching from anti-CD20 medications to less effective fumarate therapies is linked to reduced healthcare visits and costs related to infections after a year, without affecting the rate of relapses in stable multiple sclerosis (MS). That’s according to an analysis of a U.S. healthcare claims database, which compared switchers against people who stayed on CD20 inhibitors. […] The post Switching from CD20 inhibitors to fumarates may be OK in stabl…